$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

$nbix Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000091447524000117 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$590.2M	$515.3M
YoY Change	30.37%	22.57%
Cost Of Revenue	$9.200M	$7.500M
YoY Change	-20.0%	-11.76%
Gross Profit	$581.0M	$507.8M
YoY Change	31.69%	23.28%
Gross Profit Margin	98.44%	98.54%
Selling, General & Admin	$242.0M	$243.1M
YoY Change	9.11%	0.16%
% of Gross Profit	41.65%	47.87%
Research & Development	$191.1M	$159.4M
YoY Change	31.07%	14.27%
% of Gross Profit	32.89%	31.39%
Depreciation & Amortization	$7.300M	$6.200M
YoY Change	43.14%	51.22%
% of Gross Profit	1.26%	1.22%
Operating Expenses	$433.1M	$402.5M
YoY Change	17.82%	5.31%
Operating Profit	$145.4M	$105.3M
YoY Change	97.55%	-192.21%
Interest Expense	-$46.80M	-$64.80M
YoY Change	-197.5%	-5990.91%
% of Operating Profit	-32.19%	-61.54%
Other Income/Expense, Net	-$46.80M	-$64.80M
YoY Change	-197.5%	-694.5%
Pretax Income	$98.60M	$34.50M
YoY Change	-18.91%	-133.4%
Income Tax	$33.60M	-$8.900M
% Of Pretax Income	34.08%	-25.8%
Net Earnings	$65.00M	$43.40M
YoY Change	-31.94%	-156.66%
Net Earnings / Revenue	11.01%	8.42%
Basic Earnings Per Share	$0.64	$0.43
Diluted Earnings Per Share	$0.63	$0.42
COMMON SHARES
Basic Shares Outstanding	100.6M shares	99.51M shares
Diluted Shares Outstanding	103.9M shares	103.6M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.039B	$1.211B
YoY Change	6.37%	35.32%
Cash & Equivalents	$139.7M	$396.3M
Short-Term Investments	$899.2M	$814.3M
Other Short-Term Assets	$120.2M	$100.5M
YoY Change	19.48%	-11.22%
Inventory	$42.50M	$37.20M
Prepaid Expenses
Receivables	$468.2M	$450.7M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.670B	$1.799B
YoY Change	11.57%	25.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.10M	$346.1M
YoY Change	-46.28%	451.11%
Goodwill	$5.700M	$5.700M
YoY Change	0.0%	1.79%
Intangibles	$33.50M	$34.30M
YoY Change	-9.21%	-7.8%
Long-Term Investments	$781.4M	$863.9M
YoY Change	51.55%	127.16%
Other Assets	$57.80M	$429.1M
YoY Change	-86.07%	1623.29%
Total Long-Term Assets	$1.635B	$1.673B
YoY Change	46.46%	80.52%
TOTAL ASSETS
Total Short-Term Assets	$1.670B	$1.799B
Total Long-Term Assets	$1.635B	$1.673B
Total Assets	$3.305B	$3.472B
YoY Change	26.48%	47.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$264.0M	$308.5M
YoY Change	-32.58%	-13.27%
Accrued Expenses	$129.9M	$118.9M
YoY Change	633.9%	575.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$122.8M
YoY Change	-100.0%
Total Short-Term Liabilities	$398.5M	$712.9M
YoY Change	-31.59%	90.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$141.1M	$373.4M
YoY Change	-20.55%	804.12%
Total Long-Term Liabilities	$141.1M	$373.4M
YoY Change	-20.55%	804.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$398.5M	$712.9M
Total Long-Term Liabilities	$141.1M	$373.4M
Total Liabilities	$795.8M	$1.086B
YoY Change	4.7%	60.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$48.70M	-$113.7M
YoY Change	-87.45%	-76.48%
Common Stock	$2.555B	$2.497B
YoY Change	13.98%	15.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.509B	$2.386B
YoY Change
Total Liabilities & Shareholders Equity	$3.305B	$3.472B
YoY Change	26.48%	47.15%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$65.00M	$43.40M
YoY Change	-31.94%	-156.66%
Depreciation, Depletion And Amortization	$7.300M	$6.200M
YoY Change	43.14%	51.22%
Cash From Operating Activities	$64.60M	$130.3M
YoY Change	-64.03%	-204.07%
INVESTING ACTIVITIES
Capital Expenditures	$11.60M	$11.20M
YoY Change	70.59%	31.76%
Acquisitions
YoY Change
Other Investing Activities	-$16.60M	-$43.80M
YoY Change	-86.06%	30.36%
Cash From Investing Activities	-$28.20M	-$55.00M
YoY Change	-77.6%	30.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-293.0M	69.90M
YoY Change	-10203.45%	752.44%
NET CHANGE
Cash From Operating Activities	64.60M	130.3M
Cash From Investing Activities	-28.20M	-55.00M
Cash From Financing Activities	-293.0M	69.90M
Net Change In Cash	-256.6M	145.2M
YoY Change	-553.36%	-191.26%
FREE CASH FLOW
Cash From Operating Activities	$64.60M	$130.3M
Capital Expenditures	$11.60M	$11.20M
Free Cash Flow	$53.00M	$119.1M
YoY Change	-69.33%	-189.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	170400000	usd
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	170400000	usd
CY2024Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	122800000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	170100000	usd
CY2024Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	136200000	usd
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	36700000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	35900000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	712900000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	654800000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	252900000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	258300000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120500000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106300000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1086300000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1019400000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000.0	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000.0	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100600000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100600000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98700000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98700000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2496400000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2382000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3300000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7000000.0	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113700000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157100000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2386100000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2232000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3472400000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3251400000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7500000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8500000	usd
CY2024Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	159400000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	139500000	usd
CY2024Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	6000000.0	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	143900000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	243100000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	242700000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	416000000.0	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	534600000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	99300000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-114200000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1100000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1100000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1600000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2200000	usd
CY2024Q1	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	88700000	usd
CY2023Q1	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	0	usd
CY2024Q1	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	23400000	usd
CY2023Q1	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	9800000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-64800000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10900000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34500000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-103300000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8900000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26700000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	43400000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76600000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	500000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-1200000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3200000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000000.0	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	39700000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71400000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99800000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97100000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103600000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97100000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2232000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	43400000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3700000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44500000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	69900000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2386100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1707800000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76600000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5200000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39900000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8200000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1684500000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	43400000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76600000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	44500000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	39900000	usd
CY2024Q1	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	88700000	usd
CY2023Q1	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	0	usd
CY2024Q1	us-gaap	Depreciation Depreciation	5300000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	4100000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	7100000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2100000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1600000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2200000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-15600000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-31600000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3400000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-100000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11300000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41700000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1100000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1800000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-18600000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6700000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	2800000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	24300000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	130300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-125200000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	320100000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	206200000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	276300000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	203900000	usd
CY2024Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	31300000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11200000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55000000.0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42100000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	69900000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8200000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69900000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8200000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	145200000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-159100000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	259100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	270700000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	404300000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111600000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1100000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	600000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	200000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	200000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	815700000	usd
CY2024Q1	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	100000	usd
CY2024Q1	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	1500000	usd
CY2024Q1	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	814300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	781700000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	300000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	1500000	usd
CY2023Q4	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	780500000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	701400000	usd
CY2024Q1	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	900000	usd
CY2024Q1	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	1900000	usd
CY2024Q1	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	700400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	684600000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	3400000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	500000	usd
CY2023Q4	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	687500000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	12600000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	11200000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2024Q1	us-gaap	Investments Investments	2082500000	usd
CY2023Q4	us-gaap	Investments Investments	1889000000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	18100000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	21500000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	12000000.0	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9700000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7500000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12300000	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	37600000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	43500000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	400000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5200000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	37200000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	38300000	usd
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	185900000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	139300000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	42600000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	86200000	usd
CY2024Q1	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	35300000	usd
CY2023Q4	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	45700000	usd
CY2024Q1	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	41300000	usd
CY2023Q4	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	44300000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	24800000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	24400000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	87300000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	34300000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	108900000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	417200000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	448800000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	101100000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	96000000.0	usd
CY2024Q1	nbix	Prescription Drug Fee Noncurrent PrescriptionDrugFeeNoncurrent	19400000	usd
CY2023Q4	nbix	Prescription Drug Fee Noncurrent PrescriptionDrugFeeNoncurrent	10300000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120500000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106300000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	396300000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103800000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	8000000.0	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	7800000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	404300000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111600000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5800000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-100000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	5700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3600000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3600000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3600000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3600000	usd
CY2024Q1	nbix	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	13700000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	9400000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4100000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	400000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2024Q1	nbix	Operating Lease Cost Net OperatingLeaseCostNet	9000000.0	usd
CY2023Q1	nbix	Operating Lease Cost Net OperatingLeaseCostNet	4100000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	6100000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4400000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	26900000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	1300000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	34700000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	34000000.0	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	34800000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	35600000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	1700000	usd
CY2024Q1	nbix	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	211400000	usd
CY2024Q1	nbix	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	4300000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	377400000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	12400000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	89500000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	287900000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35000000.0	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	252900000	usd
CY2024Q1	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year One NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearOne	15400000	usd
CY2024Q1	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Two NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo	23600000	usd
CY2024Q1	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Three NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree	24300000	usd
CY2024Q1	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Four NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour	25100000	usd
CY2024Q1	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced After Year Four NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour	223500000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	79100000	usd
CY2024Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-9600000	usd
CY2024Q1	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	88700000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	43400000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	43400000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-76600000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-76600000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99800000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97100000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3800000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103600000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97100000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1700000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15500000	shares
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0000914475-24-000117-index-headers.html	Edgar Link	pending
0000914475-24-000117-index.html	Edgar Link	pending
0000914475-24-000117.txt	Edgar Link	pending
0000914475-24-000117-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nbix-20240331.htm	Edgar Link	pending
nbix-20240331.xsd	Edgar Link	pending
nbix-20240331_g1.jpg	Edgar Link	pending
q1-2024xexhibit101.htm	Edgar Link	pending
q1-2024xexhibit102.htm	Edgar Link	pending
q1-2024xexhibit311.htm	Edgar Link	pending
q1-2024xexhibit312.htm	Edgar Link	pending
q1-2024xexhibit32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
nbix-20240331_cal.xml	Edgar Link	unprocessable
nbix-20240331_lab.xml	Edgar Link	unprocessable
nbix-20240331_pre.xml	Edgar Link	unprocessable
nbix-20240331_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nbix-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

2024 Q2 Form 10-Q Financial Statement

#000091447524000117 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX NEUROCRINE BIOSCIENCES INC Stock $nbix

2024 Q2 Form 10-Q Financial Statement

#000091447524000117 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix